Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Takeda and Affymax provide update for Hematide in chemotherapy-induced anemia

Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.

28 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

New therapeutic platform technology tackles major diseases

A spin out company from basic structural biology, Asterion Ltd., has led to new technology that provides a way of creating therapeutic proteins to tackle major diseases such as cancer, diabetes and infertility.

8 Aug 2008

Findings may aid in bone marrow transplants, blood diseases

New research sheds light on the biological events by which stem cells in the bone marrow develop into the broad variety of cells that circulate in the blood. The findings may help improve the success of bone marrow transplants and develop better treatments for life-threatening blood diseases.

5 Aug 2008

A new target for malaria drugs

The malaria parasite has waged a successful guerrilla war against the human immune system for eons, but a study in this week's Journal of Biological Chemistry has exposed one of the tricks malaria uses to hide from the immune proteins, which may aid in future drug development.

4 Aug 2008

Scientist warns about granite bench tops and radiation

Professor Llope reportedly tested 55 stones of 25 varieties of granite stones purchased from local dealers and found some homeowners would be exposed to 100 millirems of radiation in just a few months - this exceeds the annual exposure limit set by the Department of Energy for visitors to nuclear laboratories.

30 Jul 2008

Eroded telomeres are behind dyskeratosis congentia aging syndrome

Each time a cell divides, the protective caps at the ends of chromosomes shorten - and when these caps are gone, so are we. Now, by using an unconventional strategy to shorten telomeres in mice, researchers at Rockefeller University have not only created the first faithful mouse model for studying a rare yet fatal premature aging syndrome, but they have revealed the molecular defect behind the disease.

30 Jul 2008

Hormone deprivation therapy - used for prostate cancer - may cause recall and concentration problems

A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients--such as in the ability to recall and concentrate.

28 Jul 2008

New technique measures formation of clumps of proteins in protein-based pharmaceuticals

Scientists at the National Institute of Standards and Technology (NIST) have developed a technique to measure the formation of clumps of proteins in protein-based pharmaceuticals.

23 Jul 2008

Malaria prevention in schools reduces anaemia and improves educational potential in Kenyan school kids

Providing preventive treatment for malaria, given once per term, dramatically reduces rates of malaria infection and anaemia among schoolchildren, and significantly improves their cognitive ability, according to new research published in the Lancet.

16 Jul 2008

New understanding of fetal hemoglobin regulation in patients with sickle cell disease

Although sickle cell disease is a single-gene disorder, its symptoms are highly variable. In a study published online July 14 by the Proceedings of the National Academy of Sciences, scientists at Children's Hospital Boston and the Dana Farber Cancer Institute (DFCI), in collaboration with the Broad Institute of MIT and Harvard, report five gene variants that could potentially be helpful in predicting sickle cell disease severity, perhaps even leading to better treatment approaches in the future.

15 Jul 2008

Malaria prevention in schools reduces anaemia and improves educational potential in Kenyan school children

10 Jul 2008

Discovery of molecule that kills kidney cancer cells

Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But that could change, thanks to a new molecule found by Stanford University School of Medicine researchers that kills kidney cancer cells. Ideally, the researchers said, a drug created from this molecule would help fight the life-threatening disease while leaving patients' kidneys intact.

7 Jul 2008

Hydroxyurea treatment for sickle cell underused by doctors

Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.

17 Jun 2008

"HiCy" drug regimen reverses multiple sclerosis symptoms in selected patients

A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report. The findings in nine people, most of whom had failed all other treatments, suggest new ways to treat a disease that tends to progress relentlessly.

10 Jun 2008

NIDA highlights best drug abuse treatment approaches at blending conference

The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.

2 Jun 2008

Avoiding spleen removal for Cooley's anemia sufferers

Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia. Along with sickle-cell anemia, Cooley's anemia is the most commonly inherited disease in the world, affecting many people of Mediterranean descent, and 20 out of every 100,000 African-Americans. The World Health Organization estimates that between 50,000-100,000 children are born with the disease each year.

27 May 2008

Researchers map iron transport protein - may help people suffering from blood iron disorders

Montana State University scientists in the Department of Chemistry and Bio-chemistry published new research this week that could one day affect the lives of millions around the world who suffer from blood iron disorders.

21 May 2008

Trends of vitamin B6 status in US population sample identified in study

In an epidemiological study, Tufts University researchers identified trends of vitamin B6 status in a sample of the United States population based on measures of plasma pyridoxal 5'- phosphate (PLP) levels in the bloodstream. Plasma PLP is the indicator used by the federal government to set the current Recommended Dietary Allowance (RDA) of vitamin B6, a nutrient essential for red blood cell function and important for maintaining a healthy immune system and blood glucose levels.

20 May 2008

FDA approves Entereg (alvimopan) to restore bowel function

The U.S. Food and Drug Administration approved Entereg (alvimopan) today to accelerate the restoration of normal bowel function in patients 18 years and up who have undergone partial large or small bowel resection surgery. Entereg will be used in hospitalized patients who can receive no more than 15 doses.

20 May 2008